Werfen today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Aptiva® ...

1. What is antiphospholipid syndrome (APS)? Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the patient’s immune system makes antibodies (antiphospholipid antibodies [aPL]) ...

Antiphospholipid syndrome, also known as ‘Hughes Syndrome’, is an autoimmune disease characterised by a set of clinical manifestations, almost all of which are direct or indirect sequelae of a ...

Objective Chronic abdominal aortic occlusive disease (CAAOD) is an uncommon manifestation of antiphospholipid syndrome (APS), impacting cardiovascular health and peripheral arterial circulation. We ...

Objectives To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations ...

The pregnant woman had delivered a healthy preterm baby weighing 1.2 kg following an emergency cesarean section and an ...

The reagents are meant for measuring aCL and aβ2GP1 antibody levels in human serum to aid the diagnosis of primary and secondary APS.

The treatment of thrombosis as well as the prevention of recurrent thrombosis in APS has been focused on utilizing antithrombotic medications. Recurrences, in spite of treatment, have been ...

Patients with systemic lupus erythematosus (SLE) who test positive for antiphospholipid antibodies (aPLs) are at a significantly higher risk of developing diffuse alveolar hemorrhage (DAH), according ...

RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Antiphospholipid Syndrome. According to GlobalData, Phase I drugs for Antiphospholipid Syndrome does not ...